New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMazdutide vs Dermorphin

Mazdutide vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Mazdutide
Recovery & Repair
Dermorphin
Summary
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
~7 days
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
SubQ
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
1.5 mg → 3 mg → 4.5 mg → 6 mg
Not established for human use; research doses vary widely
Frequency
Once weekly
Not established
Key Benefits
  • Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
  • Significant reduction in liver fat content (NAFLD/MASH potential)
  • Improves HbA1c and fasting glucose in type 2 diabetes
  • Favorable lipid profile changes (reduced triglycerides)
  • Once-weekly subcutaneous dosing
  • Potential for superior weight loss vs GLP-1 monotherapy
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Nausea
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +3 more
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With